|
|
Дата |
|---|
| 27.10.2026 |
| 26.10.2026 |
| 23.10.2026 |
| 22.10.2026 |
| 21.10.2026 |
| 20.10.2026 |
| 19.10.2026 |
| 16.10.2026 |
| 15.10.2026 |
| 14.10.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
2.96
|
2.99
|
2.96
|
2.83
|
3.00
|
2.95
|
|
|
654 571.15
|
1 721.00
|
|
2.94
|
3.05
|
3.13
|
2.90
|
3.15
|
2.94
|
|
|
905 493.69
|
1 574.00
|
|
3.10
|
3.30
|
3.22
|
3.08
|
3.30
|
3.10
|
|
|
529 746.51
|
949.00
|
|
3.13
|
3.33
|
3.28
|
3.06
|
3.45
|
3.30
|
|
|
658 248.21
|
1 514.00
|
|
3.37
|
3.41
|
3.05
|
3.00
|
3.59
|
3.33
|
|
|
1 395 172.18
|
2 747.00
|
|
3.05
|
3.22
|
3.33
|
2.95
|
3.5999
|
2.99
|
|
|
1 929 945.09
|
3 145.00
|
|
3.33
|
3.55
|
3.27
|
3.05
|
3.35
|
3.29
|
|
|
1 239 063.41
|
2 754.00
|
|
3.15
|
3.40
|
3.96
|
3.05
|
4.00
|
3.06
|
|
|
2 212 406.87
|
3 554.00
|
|
3.85
|
3.96
|
3.66
|
3.40
|
4.05
|
3.95
|
|
|
2 255 252.31
|
4 037.00
|
|
3.55
|
3.79
|
3.44
|
3.415
|
4.36
|
3.645
|
|
|
4 496 595.73
|
7 521.00
|
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.